Kiniksa Pharmaceuticals Ltd. (KNSA)
| Market Cap | 1.34B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -139.52M |
| Shares Out | 65.96M |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $19.72 |
| Previous Close | $19.77 |
| Change ($) | -0.05 |
| Change (%) | -0.25% |
| Day's Open | 20.06 |
| Day's Range | 19.06 - 20.48 |
| Day's Volume | 422,836 |
| 52-Week Range | 11.00 - 26.00 |
HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on M...
- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab –
– Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously – – Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously –
- R eceptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous –
HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on T...
- PDUFA goal date of March 21, 2021 - - Filing based on positive data from RHAPSODY , which achieved its primary and all major secondary endpoints - - Rilonacept BLA for CAPS transferred to K...
Primary and secondary efficacy endpoints achieved statistical significance; mavrilimumab reduced risk of flare and increased sustained remission Primary and secondary efficacy endpoints achiev...
HAMILTON, Bermuda, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immun...
Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020 Kiniksa expects to initiate a dose-ranging Phase 2b clinica...
- Mavrilimumab r educe d t ime - to - f lare and i ncrease d s ustained r emission in Phase 2 giant cell arteritis clinical t rial - - Primary and secondary efficacy endpoints achieved statist...
- Primary and secondary efficacy endpoints statistically significant - - Primary and secondary efficacy endpoints statistically significant -
- Virtual e vent to take place from 8:00 a.m. to 9: 3 0 a.m. E D T -
- Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT- - Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT-
HAMILTON, Bermuda , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare...
HAMILTON, Bermuda, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
HAMILTON, Bermuda, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on ...
– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year –
HAMILTON, Bermuda, July 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381...
HAMILTON, Bermuda, July 20, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100...
HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares were trading higher Monday after the company's Phase 3 trial of Rilonacept showed statistically significant results.
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
HAMILTON, Bermuda, June 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and c...
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma
HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and c...
HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and co...
Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
HAMILTON, Bermuda, May 18, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 ...
HAMILTON, Bermuda, May 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 2,400,000 ...
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including ear...
As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals
- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 - - Statistically significant secondary efficacy endpo...
Is (KNSA) Outperforming Other Medical Stocks This Year?
The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.
- All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned - - Consortium of U.S. aca...
- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for ...
These three clinical-stage biotechs could all double in value before year's end.
Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta
HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of K...
A much-needed vote of confidence lifted an entire industry.
HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference ...
The company's lead drug candidate earned Breakthrough Therapy designation from American regulators.
Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for ri...
HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
– Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 – – Operating plan funded into 2H 2021; no current plan to raise additional capital prior ...
Some investors think the market's been too hard on these drugmakers.
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Data reinforce the scientific evidence supporting the potential treatment of chronic pruritic diseases through OSMRβ inhibition Data reinforce the scientific evidence supporting the potential ...
About KNSA
Kiniksa Pharmaceuticals,, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis... [Read more...]
| Industry Biotechnology | IPO Date May 24, 2018 |
| CEO Sanj K. Patel | Employees 135 |
| Stock Exchange NASDAQ | Ticker Symbol KNSA |
Analyst Forecasts
According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is 34.00, which is an increase of 72.41% from the latest price.